Low Back Pain – Pipeline Review, H1 2018; New Report Launched
Low back pain can happen anywhere below the ribs and above the legs. Causes of low back pain include overuse, strain, or injury, aging, arthritis, illness and cancer involving the spine. Symptoms include tingling or burning sensation, a dull achy feeling, or sharp pain and weakness in legs or feet. Treatment includes pain medications such NSAIDs (non-steroidal anti-inflammatory drugs) or opioids and muscle relaxants.
Report Highlights
Low Back Pain - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Low Back Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Low Back Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Low Back Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 10, 5, 4, 1 and 1 respectively.
Low Back Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences,
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Low Back Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Low Back Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Low Back Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Low Back Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Low Back Pain (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Low Back Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Low Back Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Spanning over 105 pages "Low Back Pain - Pipeline Review, H1 2018" report covers Introduction, Report Coverage, Low Back Pain - Overview, Low Back Pain -
For more information Visit at: https://www.drugpipeline.net/global-markets-direct/low-back-pain-pipeline-review-h1-2018
Find all Pharma and Healthcare Reports at - http://www.drugpipeline.net/catalog/pharma-healthcare
Related Reports;
Guillain-Barre Syndrome - Pipeline Review, H1 2018 - Visit at - https://www.drugpipeline.net/global-markets-direct/guillain-barre-syndrome-pipeline-review-h1-2018
Rett Syndrome - Pipeline Review, H1 2018 - Visit at - https://www.drugpipeline.net/global-markets-direct/rett-syndrome-pipeline-review-h1-2018
About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.
For more information on this press release visit: http://www.sbwire.com/press-releases/low-back-pain-pipeline-review-h1-2018-new-report-launched-977572.htm
Media Relations Contact
DrugPipeline.net
Telephone: 1-302-703-9904
Email: Click to Email
Web: https://www.drugpipeline.net/global-markets-direct/low-back-pain-pipeline-review-h1-2018



Weather Analytics Acquires & Merges with Athenium Inc.
Rivera proposes $299M budget with 2 percent tax hike
Advisor News
- Report: Many Americans paying up to 45% of annual income on auto loans
- Latest state budget raises taxes on Californians, ignores voter priorities
- What advisors and clients must know about Roth conversions
- Worker retirement confidence dips to lowest level in a decade
- What’s behind private equity investment in insurance brokerages
More Advisor NewsAnnuity News
- Globe Life Inc. (NYSE: GL) Making Surprising Moves in Tuesday Session
- Why annuities are gaining traction with younger investors
- Best’s Special Report: U.S. Life/Annuity Industry Sees Bottom-Line Growth Despite 18% Decline in Total Income in First-Quarter 2026
- Globe Life Inc. (NYSE: GL) Records 52-Week High Thursday Morning
- Fortitude Re Completes $500 Million FABN Issuance
More Annuity NewsHealth/Employee Benefits News
- The one skyrocketing cost voters keep thinking about
- REP. GOLDMAN INTRODUCES THE BETTER CARE, BETTER COST ACT TO STRENGTHEN MEDICAID
- New task force targets rising health insurance costs
- Thousands in Wyoming are paying sky-high health insurance costs. A new task force is digging into why
- Bohannan tours Park Place Long-Term Care nursing home in Mt. Pleasant
More Health/Employee Benefits NewsLife Insurance News
- Avoid the ‘summertime slump:’ Strategies to remain productive
- Globe Life Inc. (NYSE: GL) Making Surprising Moves in Tuesday Session
- Symetra Partners with PlanSource to Streamline Workforce Benefits Administration
- Royal Neighbors of America achieves record growth
- Only 1 in 4 Americans Think Now Is A Good Time To Invest, Allianz Life Study Finds
More Life Insurance News